Outfitter Financial LLC Sells 5,720 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Outfitter Financial LLC cut its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 30.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,065 shares of the company’s stock after selling 5,720 shares during the period. Outfitter Financial LLC’s holdings in Pacira BioSciences were worth $246,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the company. Caitlin John LLC boosted its stake in shares of Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after purchasing an additional 1,776 shares during the period. Nisa Investment Advisors LLC boosted its position in Pacira BioSciences by 495.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after buying an additional 2,749 shares during the period. Virtus Investment Advisers Inc. bought a new position in Pacira BioSciences in the 3rd quarter worth about $98,000. CWM LLC grew its stake in Pacira BioSciences by 713.6% in the 3rd quarter. CWM LLC now owns 6,517 shares of the company’s stock worth $98,000 after acquiring an additional 5,716 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Pacira BioSciences by 62.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company’s stock worth $134,000 after acquiring an additional 3,404 shares during the period. 99.73% of the stock is currently owned by institutional investors.

Pacira BioSciences Stock Performance

Shares of Pacira BioSciences stock opened at $25.74 on Friday. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $31.67. The firm’s 50 day moving average price is $22.49 and its 200-day moving average price is $18.31. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PCRX. Royal Bank of Canada reissued a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. HC Wainwright reissued a “buy” rating and set a $39.00 price target on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Needham & Company LLC raised their price target on Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and upped their price objective for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. Finally, Barclays cut their target price on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $22.78.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.